Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx	$12.91 -1.7%	$12.43	$10.80 ▼ $34.50	$186.89M	N/A	149,120 shs	29,163 shs
OSTX OS Therapies	$1.70 +6.3%	$1.62	$1.12 ▼ $7.00	$47.77M	N/A	469,661 shs	268,763 shs
SLS SELLAS Life Sciences Group	$1.78 -7.8%	$1.41	$0.77 ▼ $2.12	$177.60M	2.34	1.51 million shs	2.40 million shs
TLSA Tiziana Life Sciences	$1.39 -2.8%	$1.21	$0.63 ▼ $1.91	$167.09M	0.29	476,901 shs	310,072 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx	-1.68%	-1.90%	+4.53%	+2.52%	-62.42%
OSTX OS Therapies	+6.25%	+17.24%	-6.59%	+3.66%	+169,999,900.00%
SLS SELLAS Life Sciences Group	-7.77%	+4.71%	+26.24%	+56.14%	+28.99%
TLSA Tiziana Life Sciences	-2.80%	-2.11%	+6.11%	+23.01%	+51.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INBX Inhibrx	2.2442 of 5 stars	0.0	2.0	4.6	3.0	2.5	1.3
OSTX OS Therapies	1.8762 of 5 stars	3.7	0.0	0.0	1.2	1.7	0.6
SLS SELLAS Life Sciences Group	0.5232 of 5 stars	0.0	2.0	0.0	4.0	0.0	0.6
TLSA Tiziana Life Sciences	0.9878 of 5 stars	0.0	5.0	0.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INBX Inhibrx	2.00	Hold	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	958.82% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OSTX, SLS, INBX, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	INBX Inhibrx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
3/31/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INBX Inhibrx	$200K	934.43	N/A	N/A	N/A	∞
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	$1M	177.60	N/A	N/A	($0.25) per share	-7.12
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INBX Inhibrx	-$154.96M	$116.75	0.11	N/A	N/A	N/A	-113.74%	-80.56%	6/16/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
SLS SELLAS Life Sciences Group	-$37.34M	-$0.38	N/A	N/A	N/A	N/A	-629.46%	-178.65%	8/12/2025 (Estimated)
TLSA Tiziana Life Sciences	-$17.69M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OSTX, SLS, INBX, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
3/20/2025	Q4 2024	SLS SELLAS Life Sciences Group	-$0.1067	-$0.08	+$0.0267	-$0.08	N/A	N/A
3/17/2025	Q4 2024	INBX Inhibrx	-$2.88	-$3.09	-$0.21	-$3.09	N/A	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INBX Inhibrx	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INBX Inhibrx	N/A	4.70	4.70
OSTX OS Therapies	N/A	0.76	0.76
SLS SELLAS Life Sciences Group	N/A	2.26	2.26
TLSA Tiziana Life Sciences	N/A	0.85	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INBX Inhibrx	82.46%
OSTX OS Therapies	N/A
SLS SELLAS Life Sciences Group	17.38%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
INBX Inhibrx	17.09%
OSTX OS Therapies	13.80%
SLS SELLAS Life Sciences Group	1.40%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INBX Inhibrx	166	14.48 million	11.26 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
SLS SELLAS Life Sciences Group	10	99.78 million	69.54 million	Not Optionable
TLSA Tiziana Life Sciences	8	116.85 million	63.43 million	Optionable

OSTX, SLS, INBX, and TLSA Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?

May 28 at 1:36 AM | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Here's What Happened

May 27 at 1:37 AM | americanbankingnews.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.com

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab

April 3, 2025 | markets.businessinsider.com

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins

April 2, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

April 2, 2025 | globenewswire.com

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS

March 25, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, SLS, INBX, and TLSA Company Descriptions

Inhibrx NASDAQ:INBX

$12.91 -0.22 (-1.68%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$12.90 -0.01 (-0.08%)

As of 05/28/2025 04:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

OS Therapies NYSE:OSTX

$1.70 +0.10 (+6.25%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.64 -0.05 (-3.24%)

As of 05:44 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

SELLAS Life Sciences Group NASDAQ:SLS

$1.78 -0.15 (-7.77%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.86 +0.08 (+4.72%)

As of 06:34 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Tiziana Life Sciences NASDAQ:TLSA

$1.39 -0.04 (-2.80%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 05/28/2025 07:21 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time